AGENUS INC Lessee, Operating Lease, Liability, Undiscounted Excess Amount
AGENUS INC (AGEN) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $5.76 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-16
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5.76M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $44.42M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $54.20M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $61.72M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $5.76M 10-K · filed 2026-03-16 |
| 2024-12-31 | $44.42M 10-K · filed 2025-03-17 |
| 2023-12-31 | $54.20M 10-K · filed 2024-03-14 |
| 2022-12-31 | $61.72M 10-K · filed 2023-03-16 |
| 2021-12-31 | $60.16M 10-K · filed 2022-03-01 |
| 2020-12-31 | $66.06M 10-K · filed 2021-03-16 |
| 2020-09-30 | $12.23M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $12.86M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $13.19M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $6.35M 10-K · filed 2020-03-16 |
| 2019-09-30 | $6.67M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $5.48M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $3.21M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |